Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18540694 | 0.85 | L3MBTL1 (0.43) | RIPK1MAOBSMN1; SMN2TDP1 | |
| SCHEMBL13960060 | 0.82 | IDO1 (0.32) | IDO1 | |
| SCHEMBL13251509 | 0.81 | ENPP2 (0.43) | CYP11B1CYP11B2 | |
| SCHEMBL8081506 | 0.81 | BCL2 (0.36) | IDO1CYP1A2SMN1; SMN2 | |
| SCHEMBL13809217 | 0.81 | MAOB (0.44) | TAAR1MAOBCYP11B1CYP11B2TDP1 | |
| SCHEMBL15607566 | 0.81 | ENPP2 (0.46) | TAAR1CYP1A2 | |
| SCHEMBL16137351 | 0.81 | TAAR1 (0.43) | TAAR1IDO1CYP11B1CYP11B2TDP1 | |
| SCHEMBL13251508 | 0.79 | TSHR (0.35) | — | |
| SCHEMBL881459 | 0.78 | ESR1 (0.42) | TAAR1 | |
| SCHEMBL1811937 | 0.78 | TAAR1 (0.47) | RIPK1TAAR1IDO1AGXTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9314463-B2 | Oligomer-diarylpiperazine conjugates | NEKTAR THERAPEUTICS (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150335640-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | NEKTAR THERAPEUTICS | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335640-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | BIRC5, MTX2, IAPP | RIPK1 4402/4885TAAR1 1710/4885IDO1 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.